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Background: Combinations of disease-modifying anti-rheumatic drugs (DMARDs) are increasingly used to control
active rheumatoid arthritis (RA); however there is little information about patients’ perspectives, their expectations,
concerns and experiences of this intensive treatment.
Method: We interviewed a quota sample of 18 patients from a single tertiary outpatient clinic, stratified by gender,
ethnicity and age, based on the outpatient clinic population. Patients with early RA (<2 years) received combined
conventional DMARDs; patients with established RA (>2 years) received combined conventional DMARDs or
DMARDs with biologics.
Results: Four main themes emerged from the analytical framework: (i) patients’ expectations about the combined
treatment focuses mainly on physical symptoms; (ii) the impact of the treatment on quality of life varied with the
new medication in both groups (iii) concerns about new interventions concentrated mainly on potential side
effects; and (iv) combination therapy can be self-managed in close collaboration with clinic staff, but this requires
individualised management approaches. These themes resonate with von Korff’s collaborative management of
chronic illness model.
Conclusion: To our knowledge this is the first qualitative study that examined systematically in patients with early
and established RA their expectations, impact on quality of life, concerns about side effects and the management
of the treatment when taking combined medication with DMARDs or DMARDs and biologics. Patients have
generally positive views of combination DMARDs. Within routine practice settings, achieving medication
concordance with complex combined DMARD regimens is challenging, and the concerns vary between patients;
careful individual assessments are essential to successfully deliver such intensive treatment.
Keywords: Combination treatment, Qualitative study, Rheumatoid arthritisBackground
Combination therapy has been proven through rando-
mised controlled trials as effective in the early disease
process of Rheumatoid Arthritis (RA) [1-3]. It is now
accepted that initial combination therapy and biologic
agents are more effective than single disease-modifying
anti-rheumatic drugs (DMARDs) [4]. However biologics
are not the first treatment of choice in early RA, com-
bination of DMARDs is the first option. The debilitating* Correspondence: heidi.lempp@kcl.ac.uk
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reproduction in any medium, provided the oreffect of early RA, short-term functional impairment is
mostly caused by local and systemic inflammation,
whereas long-term untreated inflammation leads to
structural, functional and irreversible damage [5]. There
have been concerns amongst rheumatologists about the
side-effects, risks and complications of DMARDs and
the newer biologics [1]. There are major differences in
the costs of treatments, with most conventional
DMARDs costing less than £1,000 per year, whilst most
biologics including tumour necrosis factor (TNF) inhibi-
tors, cost almost £10,000 per year [6]. In addition health
expectations of patients also play a role what treatment
can be realistically offered [7]. Three recent qualitativeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and recipients of this new treatment and its combin-
ation. Patients’ responses to the newly offered treatment
in early RA tended to be more positive in comparison to
rheumatologists who expressed a degree of reluctance in
prescribing lots of medication. This divergence is not
new in RA care, as highlighted in the literature in rela-
tion to physical and psycho-social aspects of rheumatol-
ogy care and its management [9-12]. This draws
attention to how clinician rated treatments may not co-
incide with the views of patients with RA for example.
In return such disagreement may interfere with patients’
cooperation when responding to their individually tai-
lored needs. Against this background of current sea
change in the treatment of RA, the aim of our study was
to explore expectations, the impact on quality of life,
concerns and management of patients with newly diag-
nosed and established RA when in receipt of combin-
ation therapy.
Method
We decided to undertake a qualitative interview study to
obtain greater detailed understanding of patients’ daily
experiences, expectations and potential difficulties man-
aging their combination therapy. During outpatient
clinic time patients are routinely asked to complete
questionnaires, e.g. Health Assessment Questionnaires,
Disease Activity and Visual Analogue Scores to assess
their clinical outcomes. In discussion with patients they
expressed lack of motivation over time in filling in
these measures. In their opinion the given answers do
not reflect the daily reality of living with RA and self-
management. Obtaining of qualitative data via focus
groups was also considered, but proofed difficult to ar-
range due to patients other commitments, e.g. work,
family duties, caring for others.
Recruitment of patients
We studied a quota sample of 18 patients, stratified by
gender, ethnicity and disease duration (early RA diagno-
sis (< 2 years) receiving combinations of DMARDs; or
established RA (>2 years) receiving either combinations
of DMARDs or TNF inhibitors combined with metho-
trexate, or an alternative DMARDs, based on the
Rheumatology outpatient clinic population (see Table 1).
All attended a single tertiary outpatient clinic. The
DMARDs used in combination therapy included metho-
trexate, hydroxychloroquine, sulfasalazine, leflunomide,
intramuscular gold and cyclosporine. Steroid injections
or oral prednisolone were offered to patients as occa-
sional supplementary treatment; they were not a routine
part of combination therapy. The duration of receiving
combination therapy ranged from 4 months to 6 years in
the study cohort. All patients met the American Collegeof Rheumatology and European League against Rheuma-
tism criteria for RA [13,14].
Apart from the diagnosis and combined medication,
the inclusion criteria were: 18 years of age or older, and
able to understand and communicate in English. Exclu-
sion criteria: being seriously ill, or having learning, hear-
ing or communication difficulties. Eight female patients
refused to take part, due to lack of time (x5); moving
abroad (x1); being on mono-therapy (x1); and being too
unwell on combined treatment (x1).
Interview conduct
Participants were interviewed according to their
expressed preference by one researcher (HL) either face
to face in a private room in the Medical School (x14) be-
fore or after their outpatient clinic appointment; or at
home (x1) or by telephone (x3) when their RA was less
well controlled that resulted in limited mobility. Prior to
the interview the researcher obtained a written informed
consent from each interviewee. Each interview took on
average of 20–30 minutes.
The interview guide was derived from the literature
[8,11] and experiential knowledge of one author with
clinical responsibility (see Appendix 1). Three main
questions were the focus of the study, followed up by
supplementary ones: (i) what led to the decision to com-
mence you on combination therapy; (ii) what is your
understanding of the combined treatment; (iii) how do
you assess your quality of life since your commenced the
combination therapy.
A pilot study was conducted with two patients, after
which they were asked to provide feedback about the
length of the interview, feasibility, comprehensiveness
and relevance of the interview schedule [15]. Both pilot
participants positively endorsed those criteria. In
addition, one clinician (DS) assessed the content of the
two interviews and confirmed that no further amend-
ments to the interview guide were required. Both pilot
interviews were therefore included in the main study.
Our study protocol specified to approach 10–20 out-
patient attendees with RA and when saturation of
themes was reached following 18 interviews, further re-
cruitment of participants was discontinued [16,17].
Data analysis
All interviews were transcribed by two authors (HL,
DH) and uploaded to the qualitative computer software
programme NViVO 9 [18]. Qualitative content analysis
[19] was applied, including single counting and inclusion
of negative findings [20,21]. After the initial coding, an
external experienced qualitative researcher (SLH) cross-
checked the codes and an agreement between both
researchers (HL, SLH) was reached. Following the sec-
ond and third coding phase, the emerging themes were
Table 1 Socio-demographic characteristics of study cohort (=18 participants)
Gender 14 women, 4 men
Age range, mean and median Range: 21–70 years, mean: 49 years,
median: 50 years
Self-described ethnicity 1 Asian; 1 Black African; 1 Black British;
1 British Bengali; 1 Caribbean; 1 Columbian;
11 White British/English; 1 Welsh
Employment status Employed full-time x2; employed part-time x2;
self-employed x1; student fulltime x1; housewife x2;
retired x5; unemployed x5.
Registered disabled Yes: 12; No: 6
Range of year of diagnosis (median) 1966-2011 (2007)
Early RA (<2 years)/established RA (> 2 years) 8 patients/10 patients
Receipt of combined DMARDs/combined DMARDs & biologic treatment 13 patients/5 patients with RA
Range of duration of combined treatment (median) 4 - 96 months (36 months)
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ical framework identified and the theoretical concept
endorsed [22].
This meant that the known topics were grouped into
four interlinked headings (i) expectations about com-
bined therapy; (ii) impact of treatment on quality of life;
(iii) concerns about combined treatment and (iv) its
management at home. Patients’ accounts in relation to
their treatment offered and prescribed resonated well
with the central concept of von Korff ’s collaborative
management of chronic illness [23]. Elements of this no-
tion in relation to self-care [24-27], provided an import-
ant context and substantiated the relevance and
meaning for the key findings of our study [22]. Local Re-
search Ethics Committee and Research & Development
approvals were obtained.
Results
Patients with early RA (8/18) all received combined
DMARDs. Participants with established RA (10/18)
received either combined DMARDs (5/18) or DMARDs
combined with biologics (5/18). Detailed inspection of
the qualitative data identified four emerging themes
within the analytical framework, which showed some
differences between patients with early (n = 8) and estab-
lished RA (n = 10). These themes comprised: (i) patients’
expectations about combined therapy; (ii) the impact of
treatment on quality of life; (iii) concerns about com-
bined treatment; and (iv) management of combined
therapy at home.
Theme 1: Patients’ expectations about combined therapy
All patients (18/18) described in detail how and why the
decision was taken to prescribe combined treatment.
Combined therapy was commenced either because the
disease was not well controlled (10/18), and/or the
mono-therapy was not effective enough (8/18). Allpatients had experienced treatment failure at different
stages of their illness trajectory.
‘. . . so that is my story, I have been given combination
therapy and the doctor suggested this was the path I
would follow, this was the new approach now. And
quite honestly I was delighted to go along. . . I was
getting quite limited, it was impossible to fill up the
kettle or put the tap on’. (Patient 9, early RA)
‘My blood always showed inflammation, every drug I
had taken did not control the inflammation. I started
off with methotrexate [mtx] more than 24 years ago,
but I still had pain. One drug just did not work for
me. So the medical staff started me on Sulfasalazine
and I took it for one month but it did not agree with
me. Then they offered me anti-TNF [treatment] and
that really suited me and my life style’. (Patient 5,
established RA)
When asked what kind of expectations they had about
the combination therapy, regardless whether the inter-
viewees had early or established RA, all (18/18) focused
on the desire to improve their physical symptoms, e.g.
pain, mobility, fatigue and insomnia, followed by qualify-
ing that these positive enhancements would allow them
to maintain some degree of independence to carry out
activities of daily living and/or to continue with paid
work. 7/18 participants stated that their expectations
were not met, which caused dissatisfaction and ongoing
physical discomfort (See Table 2).Theme 2: The impact of treatment on quality of life
Patients’ assessments of whether their treatment was
working varied in both early and established subgroups.
The impact on their physical symptoms tended to dom-
inate, e.g. pain, swelling, stiffness, mobility and fatigue.
Table 2 Random examples of accounts of met and unmet expectations of 6/18 patients who commenced on
combination therapy
Met expectations (n = 7) Unmet expectations (n = 11)
‘I thought it could not work for me, but in fact it did, the most scaring
thing for me was not being able to walk or not being able to do
anything. But now. . . I can do a lot of things that I could not do before,
well, housework, vacuum cleaning, cooking, and a lot of few bits that
I am happy to do. (Patient 4, established RA)
‘I am a bit disappointed now, the pain is sort of coming back more
strongly now; and I had my jab [steroid injection] today. . .I find it
difficult to walk, and my ankles get weak and in my fingers I don’t
have the strength’. (Pilot Patient 1, established RA)
‘My main expectations are: being able to sleep through the night and
not being woken at 3am in the morning in pain, ability to work, I have
to function and clarity of mind; I suppose that these are the important
improvements I expect from the treatment’. (Patient 7, established RA)
‘I was expecting to get better, like giving me more freedom with my
health, mobility is the main thing and I think if you are in pain your
mood is different and it changes, you feel you are not well yourself’.
(Patient 3, early RA)
‘When I started taking the medicines at the beginning, they started
working immediately. I thought I would feel better very, very soon
and it happened [mobility fatigue], so I think all my expectations
were met’. (Patient 12, established RA)
‘The combination therapy has helped, but not as much as I hoped
it would. I think I was hoping for a miraculous change [pain, mobility]
and it did not happen’. (Patient 8, established RA)
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were unsure and 5/8 expressed satisfaction. In partici-
pants with established RA, 1/10 stated the combined
treatment did not work (received DMARDs and biolo-
gics), 3/10 expressed uncertainty and 6/10 stated con-
tentment (of which four received DMARDs and
biologics). Random examples from each group and cat-
egory are summarised in Table 3.
In relation to physical pain, a dominant symptom in
RA, one female felt no pain at all. The majority used
phrases such as ‘pain relief ’, ‘ease of pain’; ‘discomfort’,’-
cannot get rid of the pain’, ‘some pain’; ‘control of dis-
ease’; ‘not being pain free’; no pain free future’.
The reports about their quality of life since commence-
ment of combined therapy resulted in mixed descriptions:
two patients were undecided, 12/18 provided positive
answers (of which four received DMARDs and biologics),
and 4/18 were less favourable, of which one patient was on
DMARDs and biologics (which coincided with the ones
who stated unmet expectations). The broad World Health
Organisation (1997) definition of Quality of Life was
adopted in the study that related to a person’s physical
health, psychological state, level of independence, socialTable 3 Random examples of statements about whether com
Treatment is working Unsure whether treatme
Patient with early RA (n = 1 unsatisfied, n = 2 unsure, n = 5 satisfied)
‘I can move easier and some days
I do not even remember that I got RA’.
(Patient 13)
‘I would have thought the
period lasted 5–6 months
apart from the feet. But th
you know, swelling up ag
but in the initial stages I’v
say it [combination therap
did help, definitely’. (Patie
Patients with established RA (n = 1 unsatisfied, n = 3 unsure, n = 6 satisfie
‘Stiffness and pain level is much
better than it was, and generally
the scores [ESR and Disease Activity Score]
and the feelings are the same’. (Patient 10)
‘The treatment is working
free and do not have so m
I find it easier to pull mys
but there again I have be
injection, and the steroid
(Pilot Patient 2)relationships, personal beliefs and their relationship to sali-
ent features of their environment. Participants made positive
and negative references to health issues, e.g. pain, control of
RA, mobility, side effects but also to their independence,
personal relationships and change in their social life.
‘hm. . . no change [my quality of life] since I started to
be sick, because once you get RA, your life changes’.
(Patient 3, early RA)
‘I am undecided [about my quality of life]; I got into a
routine with my life’. (Patient 10, established RA)
‘The RA is completely out of sight, the medication is
now controlling it, I am so much better, and I met a
man and I eventually married him, the relationship is
so much easier, because we can do many things
together’. (Patient 16, established RA)
Theme 3: Concerns about combined treatment
When asked about their concerns about the offered and
prescribed combined treatment, many (14/18) expressed
several worries about the medication and its potential sidebination therapy is working by 6/18 participants








‘When I take the medication
I do not feel any change. I feel tired
and I am in bed most of the time.
If I want to go out sometimes I cannot go,
because I am really, really tired’. (Patient 4)
d)
, I am pain
uch deformity....
elf out of the bath,
en given a steroid
does help’.
‘Stiffness and pain are the same since I started
the combined treatment’. (Pilot Patient 1)
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negative impact), additional physical problems (e.g. deteri-
orating eye sight, damage to internal organs); anxiety about
cancer with methotrexate (e.g. immune suppression, per-
ceived as ‘strong medication); uncertainty about treatment
failure (e.g. controlling RA, quality of life); number of medi-
cations (e.g. high dose of steroids, chemicals in the body).
Table 4 provides random examples in each category.
The majority (11/18) described actual physical and sys-
temic side effects that they experienced while on com-
bination therapy. These related to weight gain and loss,
chest infections (in relation to biologics), intestinal pro-
blems (e.g. nausea, indigestion), anaemia, fatigue, loss of
hair and migraine. Some were of sufficient severity for
their medication to be temporarily discontinued. A sub-
stantial minority (8/18) needed additional top-up steroid
injections, additional blood monitoring and constant ad-
justment of their medication.
‘The first thing was visual. . . it [medication] is
changing my appearance so drastically, when I am
looking in the mirror I am not happy what I see. I
struggle to fit into my clothes that I had for quite
some time, it makes me really unhappy, how long is
this going to go on?’ (Patient 14, early RA)
‘There came a time when I had to stop the
medication, because I developed an infection in my
chest. So I had to stop the injections and start on
antibiotics, but fortunately I started on the injection
last week again’. (Patient 4, established RA)
Theme 4: Management of combined therapy at home
Most patients received verbal (14/18) and written (17/
18) information and communication in forms of leaflets
mainly from nurses and also from some doctors in the
outpatient clinic prior to their decision to commence on
the new combined therapy. All appreciated the dialogue
with medical and particularly with nursing staff, as itTable 4 Random examples of expressed concerns about side
categories by 5/18 patients
Concerns about side effects Patients’ accounts
Ambivalence ‘I had some concerns abo
because that is what I hav
to go along with it [medi
Physical problems (long-term) ‘I wanted to know wheth
chest x-rays and things lik
what would happen to m
Worries about cancer ‘In the back of my mind I
I am getting quite immun
Uncertainty about treatment failure ‘I do not find the treatme
I can only see the situatio
Number of medication ‘I mean at the beginning
I am now on, I am OK abprovided them with sufficient details to reach a joint de-
cision about when and which treatment to start and
what kind of practical adjustments were involved.
‘I got all the information from the nurse, and I read
all about the different anti-TNF treatments, and the
one with the weekly injections suited me best and it
really has helped me’. (Patient 5)
‘The staff did go through the [written] information with
me; they explained things to me that do really help. It
helped me get my head round things, yeah’. (Patient 13)
1/18 patient reported accessing relevant internet web-
sites for further information. Many (12/18) emphasised
and appreciated the support from the clinic staff that
provided them with additional relevant and ongoing re-
assurance. However, 4/18 people criticized how commu-
nication with clinic staff was frustrating at times, as
appointment times were delayed or misunderstood.
‘Today I came up to Dr. X’s clinic. I thought that was
strange because I am normally under Professor X and
I had an injection in my shoulder. But I was not
aware that I was having that [injection].... but I was
just saying to the receptionist I was waiting for a scan
on my shoulder you know. . . so I was not quite sure
what I came up for. (Patient 2)
All (18/18) patients provided detailed descriptions
about how they incorporated and practically managed
their combined medication on a daily basis, with some
(4/18) including depictions of their individual treatment
beliefs. The majority (17/18) managed well in getting
into ‘a routine’ with the use of memory aids (6/18) to
work around their personal and public engagements, in-
cluding being taught how to inject medication (biolo-
gics) subcutaneously (5/18). For many the issue of
medication was either expressed with positive (8/18) oreffects of combination medication, divided into 5
ut the side effects, but at the same time I had no choice,
e to take in order to improve my situation. . . so I was willing
cation]’. (Patient 13, early RA)
er it would affect the organs in my body, because I have had
e that, and I have blood test every month. I always worry about
y inner organs’. (Patient 8, established RA)
am worried about getting a cancer or tumour, because I am thinking
e suppressed.’ (Patient 7, established RA)
nt helped at all, as I still got pain, the drugs are not controlling the RA. . .
n getting worse’. (Patient 15, early RA).
I was a bit concerned about the medication MTX, ahm. . . but the ones
out.... I just think: there are so many tablets to take’. (Patient 6 early RA)
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that they forgot the name of their past or present medi-
cation or found it at times difficult to remember taking
the tablets. This seemed particularly true for methotrex-
ate, as the tablets are only taken once a week.
Despite changes in medication, due to unforeseen
complications or treatment failures, patients seemed to
adapt well. Nevertheless, one patient, recently diagnosed
with RA admitted that she found taking her medication
and regular blood monitoring ‘a torture’ (see Table 5).
One patient (Pilot Patient 2) described how he had
kept some injections (biologic) at home, which he was
advised by the doctor to discontinue due to a chest in-
fection. At times when he felt unwell, once every two
months, he self-medicated, because as he reported ‘I
knew the result would be good, you know’.
Discussion
To our knowledge this is the first qualitative study that
examined systematically in patients with early and estab-
lished RA their expectations, impact on quality of life,
concerns about side effects and the management of the
treatment when taking combined medication with
DMARDs or DMARDs and biologics. There was no not-
able difference by gender, ethnicity, age and disability in
patients’ accounts.
Decisions by medical staff to prescribe combined ther-
apy, according to the patients’ understanding, were ‘the
disease was not well controlled’ and ‘monotherapy was
not effective enough’ were patients’ views and show the
diversity of expressions used. Although the notions areTable 5 Random examples of accounts how participants (7/18
monitoring
Patient Management of medication (n = 5 positive attitude
Pilot Patient 1 ‘I get used to the tablets and everything and I get used
the injections on a Wednesday and the Folic Acid on a
Patient 3 ‘I take one tablet [Leflunomide] every day in the morni
When I take MTX, I take it in the morning, and the oth
both medications at once, so I always keep some time
you know that you depend on this medication, I alway
taken my medication’.
Patient 5 ‘Monday is the day when I take MTX and inject Enbrel
myself, and I hate it. I call it my ‘bad day’ like many wo
on Wednesday and that is me done for the rest of the
it is a real pain’.
Patient 6 ‘I put like a timer on my phone to remind me, so I rem
[RA medication], I just find it a lot of medication to be
it is kind of like make myself do it. . .I feel like a walking
Patient 7 ‘I know my colleagues laughed when I told them that
Dosette Box and ‘Pharmacy to you’, these are my two
of taking umpteen bottles, and keeping it away from a
with me in the handbag’.
Patient 14 ‘It is a torture really, because I struggle a lot to get the
Patient 16 ‘The blood monitoring is easy; I just go to the GP. For m
it and so that is all fine, no problem’.related they may not mirror the medical categories used,
e.g. no response, incomplete response or response to
treatment.
Within our analytical framework three key messages
emerged that appear relevant for clinical practice. Firstly,
patients’ expectations about the combined treatment fo-
cused mainly on their physical symptoms and concerns
about the side effects. Secondly, patients reported that
the efficacy of the treatment and its subsequent benefit
on their quality of life was mixed. A subgroup of
patients on DMARD and biologic seemed to be particu-
larly satisfied with the treatment offered and their qual-
ity of life. Finally most patients were able to manage
their combined treatment at home, for some with add-
itional electronic or memory aids in close ongoing dia-
logue and support from the clinic staff. This was also
highlighted in the literature [28].
During the interviews many patients alluded to the di-
verse impact that RA has on their lives with its fluctuating
nature. However, we decided to exclude these accounts
from this paper, as published elsewhere [28,29] and to re-
port the key messages that emerged from the interviews.
The introduction of DMARDs when used in combin-
ation are prescribed in varying speed during consulta-
tions, depending on patients’ medical and emotional
circumstances, with the need to continually modify
DMARD treatment. These may result in a range of dis-
ease activity scores and influence patients’ perceptions.
Moreover, intermittent gluco-corticoide treatment is
often used as part of intensive combination treatment
that may influence patients’ views.) manage their combined medication and blood
, n = 10 ambivalent attitude)
to the injections now as well. So I take MTX on a Wednesday,
Friday.... I have done it for couple of years now, so I got used to it’.
ng and the other one [MTX] I take once a week on Saturdays.
er one in the afternoon, because I was concerned about mixing
in between. I do not forget the tablets, because once you are sick
s remember and my husband is always asking me whether I have
under the skin. I call it my ‘bad day’, because I know I have to inject
rking people talk about Monday is their worst day! I take the Folic Acid
week. The monthly blood taking is the down side of this new treatment,
ember to take them [medication]. I got other tablets to take with it
taken every day, as I said I got high blood pressure as well. . . it is hard,
chemist sometimes’.
I went to Boots to buy a Dosette Box. I would be lost without my
things. . .it was easier to have a Dosette Box going on holiday, instead
toddler; when I go out for dinner, I grab my evening tablets all at once
medications out [of the package], even though I get help sometimes’.
y injections I actually went to the hospital and was taught how to do
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patients’ perception following commencement of anti-
TNF therapy [8] reached similar findings, e.g. how phys-
ical functions may improve and high expectations of
some patients were not always met. Given the long-term
disabling effect of RA, the guidelines of National Insti-
tute for Health and Clinical Excellence (NICE) [30]
recommended the benefits of particular combined
DMARDs in early and established RA. In addition “treat
to target” is now commonly recommended and its use is
supported by a number of studies [31].
Our findings resonate broadly with the collaborative
management of chronic illness model [23] that consists
of four elements, e.g. (i) collaborative definition of pro-
blems, (ii) goal setting and planning; (iii) training and
support in self-management and (iv) active and sus-
tained follow-up. Patients’ contribution to their self-care
and its medical care are clearly complementary, rather
than in competition. Both parties depend on each other
for reaching the goal of controlling the disease activity,
joint erosion and pain, including the management of
their daily activities of living and medication, within the
context of patients’ lives.
What von Korff ’s elements’ of care framework offer is
an improvement of long-term illness in a structured and
explicit way. Within the context of our study findings,
three of the four aspects of the model were adhered to
by staff and patients, whereas overt goal setting and
planning did not receive much attention. However it has
become evident from von Korff ’s publications in chronic
disease management that an effective collaborative care
approach strengthens and supports patients’ self-care in
long-term disease such as Rheumatoid Arthritis, includ-
ing their family members and carers.
Strengths and limitations of the study
The qualitative methodology adopted for the data gath-
ering has been advantageous, as patients provided first
hand and detailed views what matters most to them and
what they have difficulties with in relation to their com-
bination therapy.
One limitation was that the study cohort was recruited
from one large inner city outpatient clinic; where patients
attend from a wide geographical area and socio-
demographically diverse background, due to its tertiary sta-
tus. Moreover, the findings may not be fully generalisable
without replication, but they are timely and extend further
knowledge of how patients’ cope and manage with an ever
changing treatment approach in rheumatology care.
Finally, for reasons of lack of resources for language
interpretation, we included in the study patients who
could be interviewed in English, even if there use of
English was limited. We estimate that fewer than 5% of
all patients attending this Rheumatology clinic cannotspeak English sufficiently to communicate with staff, so
that in our view this inclusion criterion did not lead to
substantial selection bias in the study and did lead to a
representative sample of all clinic patients.
Conclusions
The treatment of patients with RA is in a stage of con-
stant flux, due to new emerging evidence about treat-
ment modalities. At each stage of such treatment
alterations, obtaining patients’ agreement will be impera-
tive, as they also need to understand and ideally adapt to
these changes. As is well known within clinical practice,
medication concordance is a complex and highly per-
sonal issue that needs careful consideration when pre-




In this interview I would like to explore three key areas:
why you started on the new treatment, what is your
understanding of the treatment and is your quality of life
different since you started treatment? At the end I would
welcome any additional information which I may have left
out but which are relevant to your experiences, including
your thoughts about taking part in a study such as this.
The interview may take up to 30 minutes and can be
paused at any time. If you provide information you do not
wish to have recorded, the tape recorder can be stopped at
any time and restarted with your agreement.
1. What led to the decision to start you on combination
therapy? Can you describe your feelings about starting the
combined treatment?
2. What is your understanding of the combined
treatment?
 What type of information did you receive about
the combination therapy and by whom?
 What expectations do you have from the
combination treatment? What outcomes are
important?
 What makes you satisfied and dissatisfied with the
treatment? e.g. range of side effects, how much do
you disclose side effects of the drugs to clinic staff
and family.
 How do you manage with the prescribed regimes,
e.g. administration, blood monitoring.
 What are your attitudes/concerns towards the
medication? In which way to they differ from the
time before you started combination therapy?
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3. How do you assess your quality of life since you
commenced the combination therapy?
 Any difference from the time before when
receiving one medication for your RA?
4. Any other issues you would like to add that were not
covered with the questions above?
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